Research programme: small molecule therapeutics - Blueprint Medicines/Roche
Latest Information Update: 03 Feb 2021
At a glance
- Originator Blueprint Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 13 Jan 2021 Blueprint Medicines amended collaboration and exclusive license agreement with Roche for the treatment of cancer
- 13 Jan 2021 Blueprint Medicines entered a collaboration and exclusive license agreement with Roche for the treatment of cancer
- 11 Jan 2021 Early research in Cancer in USA (unspecified route) prior to January 2021